Pintex Pharmaceuticals

Pintex Pharmaceuticals is a biopharmaceutical company focused on developing first-in-class therapies targeting the Pin1 enzyme, a master regulator of multiple signaling pathways involved in cancer and neurodegeneration. Founded by researchers from Beth Israel Deaconess Medical Center, the company leverages proprietary technology to develop small molecule inhibitors that block Pin1's ability to promote oncogenesis. Their primary focus has been on difficult-to-treat cancers, such as triple-negative breast cancer, where Pin1 is often overexpressed. Additionally, the company has explored the role of Pin1 in Alzheimer's disease, aiming to modulate its activity to prevent tau pathology and neurodegeneration. The company's approach seeks to address high unmet medical needs by targeting a unique proline-specific isomerase.